David Klein

MD, MBA

Investigator

Biography

My research follows two major themes: (1) health policy and (2) sepsis and critical illness.   In the area of health policy, I co-lead the Centre for the Evaluation and Optimization of Public Healthcare Finance at IHPME with Dr. Adalsteinn Brown.  We are focused on improving healthcare capital investment and evaluation with a multidisciplinary group of collaborators.   In the area of sepsis and critical illness, I lead several efforts to develop novel diagnostics and therapeutics.  I have particular expertise in healthcare innovation and commercialization in addition to clinical development strategy.

Please note: Dr. Klein is not taking any summer students.

Recent Publications

  1. Writing Committee for the REMAP-CAP Investigators, Lawler, PR, Derde, LPG, van de Veerdonk, FL, McVerry, BJ, Huang, DT et al.. Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial. JAMA. 2023;329 (14):1183-1196. doi: 10.1001/jama.2023.4480. PubMed PMID:37039790 PubMed Central PMC10326520.
  2. Klein, DJ, Veillard, J, Brown, A. Aligning goals of for-profit, not-for-profit, and public healthcare organizations by governing for quality: A model for change in the U.S. and other jurisdictions. Healthc Manage Forum. 2023;36 (4):246-248. doi: 10.1177/08404704231160274. PubMed PMID:36959688 PubMed Central PMC10291483.
  3. MacKenzie, R, Hawkins, B, Klein, DE, Ahmad, M, Norman, AK, Koon, AD et al.. The opioid industry document archive: New directions in research on corporate political strategy. Int J Drug Policy. 2023;114 :103997. doi: 10.1016/j.drugpo.2023.103997. PubMed PMID:36931180 .
  4. Smith, ML, Risse, G, Sziklas, V, Banks, S, Small, D, Frasnelli, J et al.. Neurophysiology, Neuropsychology, Epilepsy, 2022: Hills We Have Climbed and the Hills Ahead. Cognition and Sensory Systems in Healthy and Diseased Subjects. Epilepsy Behav. 2023;140 :109119. doi: 10.1016/j.yebeh.2023.109119. PubMed PMID:36804713 .
  5. Bagshaw, SM, Neto, AS, Smith, O, Weir, M, Qiu, H, Du, B et al.. Correction: Impact of renal-replacement therapy strategies on outcomes for patients with chronic kidney disease: a secondary analysis of the STARRT-AKI trial. Intensive Care Med. 2023;49 (3):381-383. doi: 10.1007/s00134-023-06976-2. PubMed PMID:36757471 .
  6. Zamzam, A, Syed, MH, Rotstein, OD, Eikelboom, J, Klein, DJ, Singh, KK et al.. Validating fatty acid binding protein 3 as a diagnostic and prognostic biomarker for peripheral arterial disease: A three-year prospective follow-up study. EClinicalMedicine. 2023;55 :101766. doi: 10.1016/j.eclinm.2022.101766. PubMed PMID:36531981 PubMed Central PMC9755058.
  7. Writing Committee for the REMAP-CAP Investigators, Higgins, AM, Berry, LR, Lorenzi, E, Murthy, S, McQuilten, Z et al.. Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial. JAMA. 2023;329 (1):39-51. doi: 10.1001/jama.2022.23257. PubMed PMID:36525245 PubMed Central PMC9857594.
  8. Das Pradhan, A, Glynn, RJ, Fruchart, JC, MacFadyen, JG, Zaharris, ES, Everett, BM et al.. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. N Engl J Med. 2022;387 (21):1923-1934. doi: 10.1056/NEJMoa2210645. PubMed PMID:36342113 .
  9. Bagshaw, SM, Neto, AS, Smith, O, Weir, M, Qiu, H, Du, B et al.. Impact of renal-replacement therapy strategies on outcomes for patients with chronic kidney disease: a secondary analysis of the STARRT-AKI trial. Intensive Care Med. 2022;48 (12):1736-1750. doi: 10.1007/s00134-022-06912-w. PubMed PMID:36331570 .
  10. Marin-Couture, E, Filion, MJ, Boukari, R, Jeejeebhoy, K, Dhaliwal, R, Brauer, P et al.. Relationship between Cardiometabolic Factors and the Response of Blood Pressure to a One-Year Primary Care Lifestyle Intervention in Metabolic Syndrome Patients. Metabolites. 2022;12 (9):. doi: 10.3390/metabo12090861. PubMed PMID:36144265 PubMed Central PMC9500796.
Search PubMed

Affiliations & Other Activities

  • Head of Business Strategy, Applied Health Research Centre, Li Ka Shing Knowledge Institute, St. Michael’s Hospital
  • Staff Physician, Critical Care, St. Michael’s Hospital
  • Assistant Professor, Faculty of Medicine, University of Toronto
  • Member, Institute for Health Policy, Management, and Evaluation, Dalla Lana School of Public Health